Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered?
Favero D, Lapuchesky LS, Poggio F, Nardin S, Perachino M, Arecco L, Scavone G, Ottonello S, Latocca MM, Borea R, Puglisi S, Cosso M, Fozza A, Spinaci S, Lambertini M. Favero D, et al. Among authors: fozza a. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):1975-1984. doi: 10.1080/14656566.2023.2293167. Epub 2024 Jan 5. Expert Opin Pharmacother. 2023. PMID: 38179613 Review.
Technological advancements and future perspectives in breast cancer radiation therapy.
Fozza A, De Rose F, De Santis MC, Meattini I, Meduri B, D'angelo E, Dei D, Figlia V, La Rocca E, Fregatti P, Satragno C, Belgioia L, Giaj-Levra N. Fozza A, et al. Expert Rev Anticancer Ther. 2023 Apr;23(4):407-419. doi: 10.1080/14737140.2023.2195167. Epub 2023 Mar 28. Expert Rev Anticancer Ther. 2023. PMID: 36960754 Review.
AIRO Breast Cancer Group Best Clinical Practice 2022 Update.
Ciabattoni A, Gregucci F, De Rose F, Falivene S, Fozza A, Daidone A, Morra A, Smaniotto D, Barbara R, Lozza L, Vidali C, Borghesi S, Palumbo I, Huscher A, Perrucci E, Baldissera A, Tolento G, Rovea P, Franco P, De Santis MC, Grazia AD, Marino L, Meduri B, Cucciarelli F, Aristei C, Bertoni F, Guenzi M, Leonardi MC, Livi L, Nardone L, De Felice F, Rosetto ME, Mazzuoli L, Anselmo P, Arcidiacono F, Barbarino R, Martinetti M, Pasinetti N, Desideri I, Marazzi F, Ivaldi G, Bonzano E, Cavallari M, Cerreta V, Fusco V, Sarno L, Bonanni A, Mangiacotti MG, Prisco A, Buonfrate G, Andrulli D, Fontana A, Bagnoli R, Marinelli L, Reverberi C, Scalabrino G, Corazzi F, Doino D, Di Genesio-Pagliuca M, Lazzari M, Mascioni F, Pace MP, Mazza M, Vitucci P, Spera A, Macchia G, Boccardi M, Evangelista G, Sola B, La Porta MR, Fiorentino A, Levra NG, Ippolito E, Silipigni S, Osti MF, Mignogna M, Alessandro M, Ursini LA, Nuzzo M, Meattini I, D'Ermo G. Ciabattoni A, et al. Among authors: fozza a. Tumori. 2022 Jul;108(2_suppl):1-144. doi: 10.1177/03008916221088885. Tumori. 2022. PMID: 36112842
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer.
Fregatti P, Gipponi M, Atzori G, Rosa R, Diaz R, Cornacchia C, Sparavigna M, Garlaschi A, Belgioia L, Fozza A, Pitto F, Boni L, Blondeaux E, Depaoli F, Murelli F, Franchelli S, Zoppoli G, Lambertini M, Friedman D. Fregatti P, et al. Among authors: fozza a. In Vivo. 2022 Mar-Apr;36(2):814-820. doi: 10.21873/invivo.12768. In Vivo. 2022. PMID: 35241537 Free PMC article.
The dosimetric impact of axillary nodes contouring variability in breast cancer radiotherapy: An AIRO multi-institutional study.
Leonardi MC, Pepa M, Luraschi R, Vigorito S, Dicuonzo S, Isaksson LJ, La Porta MR, Marino L, Ippolito E, Huscher A, Argenone A, De Rose F, Cucciarelli F, De Santis MC, Rossi F, Prisco A, Guarnaccia R, Tabarelli de Fatis P, Palumbo I, Colangione SP, Mormile M, Ravo V, Fozza A, Aristei C, Orecchia R, Cattani F, Jereczek-Fossa BA; Collaborative Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Study Group. Leonardi MC, et al. Among authors: fozza a. Radiother Oncol. 2022 Mar;168:113-120. doi: 10.1016/j.radonc.2022.01.004. Epub 2022 Jan 13. Radiother Oncol. 2022. PMID: 35033602
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D'Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F, Filippi AR. Bruni A, et al. Among authors: fozza a. Front Oncol. 2021 Nov 16;11:802949. doi: 10.3389/fonc.2021.802949. eCollection 2021. Front Oncol. 2021. PMID: 34869046 Free PMC article.
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D'Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F, Filippi AR. Bruni A, et al. Among authors: fozza a. Front Oncol. 2021 Sep 28;11:744956. doi: 10.3389/fonc.2021.744956. eCollection 2021. Front Oncol. 2021. PMID: 34650927 Free PMC article.
26 results